Viral vector production guide part 1: choosing the correct grade for your gene therapy application

James Cody is the Associate Director Technical Sales and Evaluations, Business Development, Gene Therapy CDMO Services at Charles River Laboratories. He received a PhD in cancer gene therapy from the University of Alabama at Birmingham, working primarily with oncolytic adenoviral vectors, and he completed postdoctoral training at the same institution, evaluating cancer treatment strategies based on oncolytic HSV. After his time at UAB, he then spent four years conducting research in fields including virology, cell biology, cancer, and parasitology. Dr Cody joined Vigene Biosciences in 2018, prior to its integration into Charles River in 2021.